Clinical and Safety Outcomes of Oral Antithrombotics for Stroke Prevention in Atrial Fibrillation: A Systematic Review and Network Meta-analysis

Journal of the American Medical Directors Association

Volumn 16, Issue 12, 2015, Pages 1103.e1-1103.e19

  Lin, Liang ^a   Lim, Wee Shiong ^b   Zhou, Hui Jun ^a   Khoo, Ai Leng ^a   Tan, Keng Teng ^b   Chew, Aik Phon ^b   Foo, David ^b   Chin, Jing Jih ^b   Lim, Boon Peng ^a  

^a NATIONAL HEALTHCARE GROUP   (Singapore)

^b TAN TOCK SENG HOSPITAL   (Singapore)

Author keywords

Antithrombotics; Atrial fibrillation; Elderly; Network meta analysis; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID PLUS CLOPIDOGREL; ANTICOAGULANT AGENT; APIXABAN; DABIGATRAN; EDOXABAN; RIVAROXABAN; WARFARIN; FIBRINOLYTIC AGENT;

ATRIAL FIBRILLATION; BLEEDING; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; DRUG EFFICACY; DRUG SAFETY; EMBOLISM; GASTROINTESTINAL HEMORRHAGE; HUMAN; META ANALYSIS; MORTALITY; MULTICENTER STUDY (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS; SYSTEMATIC REVIEW; TREATMENT OUTCOME; AGED; FEMALE; MALE; ORAL DRUG ADMINISTRATION; OUTCOME ASSESSMENT; STROKE;

ADMINISTRATION, ORAL; AGED; ATRIAL FIBRILLATION; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; MALE; OUTCOME ASSESSMENT (HEALTH CARE); STROKE;

EID: 84947756437     PISSN: 15258610     EISSN: 15389375     Source Type: Journal    
DOI: 10.1016/j.jamda.2015.09.008     Document Type: Review

References (78)

1. January C.T., Wann L.S., Alpert J.S., et al. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2014, 64:2246-2280.
2. Keeling D., Baglin T., Tait C., et al. Guidelines on oral anticoagulation with warfarin-fourth edition. Br J Haematol 2011, 154:311-324.
3. Cameron C., Coyle D., Richter T., et al. Systematic review and network meta-analysis comparing antithrombotic agents for the prevention of stroke and major bleeding in patients with atrial fibrillation. BMJ Open 2014, 4:e004301.
4. Ruff C.T., Giugliano R.P., Braunwald E., et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: A meta-analysis of randomised trials. Lancet 2014, 383:955-962.
5. Ansell J. New oral anticoagulants should not be used as first-line agents to prevent thromboembolism in patients with atrial fibrillation. Circulation 2012, 125:165-170. discussion 170.
6. Lip G.Y., Laroche C., Dan G.A., et al. 'Real-world' antithrombotic treatment in atrial fibrillation: The EORP-AF pilot survey. Am J Med 2014, 127:519-529.e1.
7. Eikelboom J.W., Wallentin L., Connolly S.J., et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: An analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 2011, 123:2363-2372.
8. Hori M., Matsumoto M., Tanahashi N., et al. Rivaroxaban vs. warfarin in Japanese patients with non-valvular atrial fibrillation in relation to age. Circulation 2014, 78:1349-1356.
9. Papanikolaou P.N., Christidi G.D., Ioannidis J.P. Comparison of evidence on harms of medical interventions in randomized and nonrandomized studies. CMAJ 2006, 174:635-641.
10. Hernandez I., Baik S.H., Pinera A., Zhang Y. Risk of bleeding with dabigatran in atrial fibrillation. JAMA Intern Med 2015, 175:18-24.
11. Abraham N.S., Singh S., Alexander G.C., et al. Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study. BMJ (Clinical research ed.). 2015, 350:h1857.
12. Lauffenburger J.C., Farley J.F., Gehi A.K., et al. Effectiveness and safety of dabigatran and warfarin in real-world us patients with non-valvular atrial fibrillation: A retrospective cohort study. J Am Heart Assoc 2015, 4. pii: e001798.
13. Larsen T.B., Rasmussen L.H., Gorst-Rasmussen A., et al. Myocardial ischemic events in 'real world' patients with atrial fibrillation treated with dabigatran or warfarin. Am J Med 2014, 127:329-336.e4.
14. Landis J.R., Koch G.G. The measurement of observer agreement for categorical data. Biometrics 1977, 33:159-174.
15. Sterne JAC, Higgins JPT, Reeves BC on behalf of the development group for ACROBAT-NRSI. A Cochrane Risk Of Bias Assessment Tool: for Non-Randomized Studies of Interventions (ACROBAT-NRSI), Version 1.0.0, 24 September 2014. Available at: . Accessed May 18, 2015. http://www.riskofbias.info.
16. Higgins J.P., Altman D.G., Gotzsche P.C., et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ (Clinical research ed.). 2011, 343:d5928.
17. White I.R. Multivariate random-effects meta-regression: Updates to mvmeta. Stata Journal 2011, 11:255-270.
18. Chaimani A., Higgins J.P., Mavridis D., et al. Graphical tools for network meta-analysis in STATA. PLoS One 2013, 8:e76654.
19. Jackson D., Barrett J.K., Rice S., et al. A design-by-treatment interaction model for network meta-analysis with random inconsistency effects. Stat Med 2014, 33:3639-3654.
20. Hutton B., Salanti G., Caldwell D.M., et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: Checklist and explanations. Ann Intern Med 2015, 162:777-784.
21. Gomez Quintanilla A.R., Paredes Galan E., Guitian Gonzalez A., et al. O4.03: Dabigatran etexilate and rivaroxaban show different safety and efficacy profile in very elderly patients with non valvular atrial fibrillation. Eur Geriatr Med 2014, 5:S72.
22. Ho M.H., Ho C.W., Cheung E., et al. Continuation of dabigatran therapy in "real-world" practice in Hong Kong. PLoS One 2014, 9:e101245.
23. Giugliano R.P., Ruff C.T., Braunwald E., et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013, 369:2093-2104.
24. Granger C.B., Alexander J.H., McMurray J.J.V., et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011, 365:981-992.
25. Connolly S.J., Eikelboom J., Joyner C., et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011, 364:806-817.
26. Patel M.R., Mahaffey K.W., Garg J., et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011, 365:883-891.
27. Connolly S.J., Ezekowitz M.D., Yusuf S., et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009, 361:1139-1151.
28. Connolly S.J., Pogue J., Hart R.G., et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med 2009, 360:2066-2078.
29. Connolly S., Pogue J., et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): A randomised controlled trial. Lancet 2006, 367:1903-1912. ACTIVE Writing Group of the ACTIVE Investigators1.
30. Connolly S.J., Laupacis A., Gent M., et al. Canadian Atrial Fibrillation Anticoagulation (CAFA) study. J Am Coll Cardiol 1991, 18:349-355.
31. Fontaine G.V., Mathews K.D., Woller S.C., et al. Major bleeding with dabigatran and rivaroxaban in patients with atrial fibrillation: A real-world setting. Clin Appl Thromb Hemost 2014, 20:665-672.
32. Staerk L., Olesen J.B., Torp-Pedersen C., et al. Risk of gastrointestinal adverse effects of dabigatran etexilat compared with warfarin among patients with atrial fibrillation. Eur Heart J 2014, 35:1115.
33. Laliberte F., Cloutier M., Nelson W.W., et al. Real-world comparative effectiveness and safety of rivaroxaban and warfarin in nonvalvular atrial fibrillation patients. Curr Med Res Opin 2014, 30:1317-1325.
34. Forslund T., Wettermark B., Wandell P., et al. Risks for stroke and bleeding with warfarin or aspirin treatment in patients with atrial fibrillation at different CHA(2)DS(2)VASc scores: Experience from the Stockholm region. Eur J Clin Pharmacol 2014, 70:1477-1485.
35. Hansen M.L., Sorensen R., Clausen M.T., et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med 2010, 170:1433-1441.
36. Lip G.Y., Skjoth F., Rasmussen L.H., Larsen T.B. Oral anticoagulation, aspirin, or no therapy in patients with nonvalvular AF with 0 or 1 stroke risk factor based on the CHA2DS2-VASc Score. J Am Coll Cardiol 2015, 65:1385-1394.
37. Connolly S.J., Pogue J., et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med 2009, 360:2066-2078. ACTIVE Investigators.
38. Hellemons B.S.P., Langenberg M., Lodder J., et al. Primary prevention of arterial thromboembolism in non-rheumatic atrial fibrillation in primary care: Randomised controlled trial comparing two intensities of coumarin with aspirin. BMJ 1999, 319:958-964.
39. Stroke Prevention in Atrial Fibrillation Study. Final results. Circulation 1991, 84:527-539. Stroke Prevention in Atrial Fibrillation Investigators.
40. Sato H., Ishikawa K., Kitabatake A., et al. Low-dose aspirin for prevention of stroke in low-risk patients with atrial fibrillation: Japan atrial fibrillation stroke trial. Stroke 2006, 37:447-451.
41. Posada I.S., Barriales V. Alternate-day dosing of aspirin in atrial fibrillation. Am Heart J 1999, 138:137-143.
42. Fang M.C. Implications of the new atrial fibrillation guideline. JAMA Intern Med 2015, 175:850-851.
43. Dogliotti A., Paolasso E., Giugliano R.P. Current and new oral antithrombotics in non-valvular atrial fibrillation: A network meta-analysis of 79 808 patients. Heart 2014, 100:396-405.
44. Biondi-Zoccai G., Malavasi V., D'Ascenzo F., et al. Comparative effectiveness of novel oral anticoagulants for atrial fibrillation: Evidence from pair-wise and warfarin-controlled network meta-analyses. HSR Proc Intensive Care Cardiovasc Anesth 2013, 5:40-54.
45. Schneeweiss S., Gagne J.J., Patrick A.R., et al. Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation. Circulation 2012, 5:480-486.
46. Lim W.S., Ding Y.Y. Evidence-balanced medicine: "Real" evidence-based medicine in the elderly. Ann Acad Med Singapore 2015, 44:1-5.
47. Ezekowitz M.D., Reilly P.A., Nehmiz G., et al. Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). Am J Cardiol 2007, 100:1419-1426.
48. Halperin J.L., Hankey G.J., Wojdyla D.M., et al. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the rivaroxaban once daily, oral, direct factor xa inhibition compared with vitamin k antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF). Circulation 2014, 130:138-146.
49. Hori M., Matsumoto M., Tanahashi N., et al. Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation - the J-ROCKET AF study. Circ J 2012, 76:2104-2111.
50. Halvorsen S., Atar D., Yang H., et al. Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: Observations from the ARISTOTLE trial. Eur Heart J 2014, 35:1864-1872.
51. Ogawa S., Shinohara Y., Kanmuri K. Safety and efficacy of the oral direct factor xa inhibitor apixaban in Japanese patients with non-valvular atrial fibrillation. -The ARISTOTLE-J study. Circulation 2011, 75:1852-1859.
52. Kato E.T., Giugliano R.P., Ruff C.T., et al. Efficacy and safety of edoxaban for the management of elderly patients with atrial fibrillation: Engage AF-TIMI 48. Circulation 2014, 130:A16612.
53. Yamashita T., Koretsune Y., Yasaka M., et al. Randomized, multicenter, warfarin-controlled phase II study of edoxaban in Japanese patients with non-valvular atrial fibrillation. Circulation 2012, 76:1840-1847.
54. Weitz J.I., Connolly S.J., Patel I., et al. Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thromb Haemost 2010, 104:633-641.
55. Chung N., Jeon H.K., Lien L.M., et al. Safety of edoxaban, an oral factor Xa inhibitor, in Asian patients with non-valvular atrial fibrillation. Thromb Haemost 2011, 105:535-545.
56. Liu X., Huang H., Yu J., et al. Warfarin compared with aspirin for older Chinese patients with stable coronary heart diseases and atrial fibrillation complications. Int J Clin Pharmacol Ther 2014, 52:454-459.
57. Mant J., Hobbs F.R., Fletcher K., et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): A randomised controlled trial. Lancet 2007, 370:493-503.
58. Rash A., Downes T., Portner R., et al. A randomised controlled trial of warfarin versus aspirin for stroke prevention in octogenarians with atrial fibrillation (WASPO). Age Ageing 2007, 36:151-156.
59. Gullov A.L., Koefoed B.G., Petersen P. Bleeding during warfarin and aspirin therapy in patients with atrial fibrillation: The AFASAK 2 Study. Arch Intern Med 1999, 159:1322-1328.
60. Gullov A.L., Koefoed B.G., Petersen P., et al. Fixed minidose warfarin and aspirin alone and in combination vs adjusted-dose warfarin for stroke prevention in atrial fibrillation: Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study. Arch Intern Med 1998, 158:1513-1521.
61. Petersen P., Godtfredsen J., Andersen B., et al. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet 1989, 1:175-179.
62. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet 1994, 343:687-691. Stroke Prevention in Atrial Fibrillation Investigators.
63. Connolly S.J., Laupacis A., Gent M., et al. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol 1991, 18:349-355.
64. Ng K., Shestakovska O.O., Eikelboom J.W., et al. Apixaban versus aspirin in atrial fibrillation patients >75 years old: An analysis from the AVERROES trial. Stroke 2013, 44:e187.
65. Chang H.Y., Zhou M., Tang W., et al. Risk of gastrointestinal bleeding associated with oral anticoagulants: population based retrospective cohort study. BMJ (Clinical research ed.). 2015, 350:h1585.
66. Lleva P., Aronow W.S., Gutwein A.H. Prevalence of inappropriate use of digoxin in 136 patients on digoxin and prevalence of use of warfarin or aspirin in 89 patients with persistent or paroxysmal atrial fibrillation. Am J Ther 2009, 16:e41-e43.
67. Strunets A., Mirza M., Cho C., et al. Safety and efficacy of rivaroxaban and dabigatran in octa- and nonagenerians with atrial fibrillation: A community-based experience. J Am Coll Cardiol 2014, 63(12_S).
68. Bengtson L., Chen L., MacLehose R., et al. Comparative effectiveness of dabigatran and rivaroxaban versus warfarin in patients with non-valvular atrial fibrillation. Circulation 2014, 130:A20218.
69. Graham D.J., Reichman M.E., Wernecke M., et al. Cardiovascular, bleeding, and mortality risks in elderly medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. Circulation 2015, 131:157-164.
70. Larsen T.B., Gorst-Rasmussen A., Rasmussen L.H., et al. Bleeding events among new starters and switchers to dabigatran compared with warfarin in atrial fibrillation. Am J Med 2014, 127(7):650-656. e655.
71. Larsen T.B., Rasmussen L.H., Skjoth F., et al. Efficacy and safety of dabigatran etexilate and warfarin in "real-world" patients with atrial fibrillation: A prospective nationwide cohort study. J Am Coll Cardiol 2013, 61:2264-2273.
72. Sorensen R., Gislason G., Torp-Pedersen C., et al. Dabigatran use in Danish atrial fibrillation patients in 2011: A nationwide study. BMJ Open 2013, 3. pii: e002758.
73. Kantharia B.K., Shah A.N. Combination of clopidogrel and aspirin for reduction of vascular events in patients with atrial fibrillation. Expert Rev Cardiovasc Ther 2009, 7:749-753.
74. Holmes D.R., Fountain R. Stroke prevention in atrial fibrillation: WATCHMAN versus warfarin. Expert Rev Cardiovasc Ther 2009, 7:727-729.
75. Shalimar S., Pangtey G.S., Singh K.K. Clopidogrel plus aspirin in atrial fibrillation. N Engl J Med 2009, 361:1314.
76. Ho J.C., Chang A.M., Yan B.P., et al. Dabigatran compared with warfarin for stroke prevention with atrial fibrillation: Experience in Hong Kong. Clin Cardiol 2012, 35:E40-E45.
77. Lip G.Y., Skjoth F., Rasmussen L.H., Larsen T.B. Oral anticoagulation, aspirin, or no therapy in patients with nonvalvular AF with 0 or 1 stroke risk factor based on the CHA2DS2-VASc score. J Am Coll Cardiol 2015, 65:1385-1394.
78. Richard T., Butaffuoco F., Vanhaeverbeek M. Clopidogrel plus aspirin in atrial fibrillation. N Engl J Med 2009, 361:1313.